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ABSTRACT OF DISSERTATION

CHRONIC LOW INTENSITY CONTINUOUS AND INTERVAL TRAINING
PREVENT HEART FAILURE-RELATED CORONARY ARTERY STIFFNESS
Heart failure (HF) induced by aortic pressure over-load is associated with
increased coronary artery stiffness. Perivascular adipose tissue (PVAT) and
advanced glycation end products (AGE) both promote arterial stiffness. However,
the mechanisms by which coronary PVAT promotes arterial stiffness and the
efficacy of exercise to prevent coronary stiffness are unknown. The present study
hypothesized both chronic continuous and interval exercise training would
prevent coronary artery stiffness associated with inhibition of PVAT secreted
AGE and the beneficial effects of interval exercise would be greater than
continuous exercise.Yucatan mininature swine were divided into four groups:
control-sedentary (CON), aortic-banded sedentary heart failure (HF), aorticbanded HF continuous exercise trained (HF+CONT), and aortic-banded HF
interval exercise trained (HF+IT). Coronary artery stiffness was assessed by ex
vivo mechanical testing and coronary artery elastin, collagen and AGE-related
proteins were assessed by immunohistochemistry. HF promoted coronary artery
stiffness with reduced elastin content and greater AGE accumulation which was
prevented by chronic continuous and interval exercise training. HF PVAT
secreted higher AGE compared with CON and was prevented in the HF+CONT
and HF+IT groups. Young healthy mouse aortas cultured in HF PVAT
conditioned media had increased stiffness, lower elastin content and AGE
accumulation compared with CON, which was prevented by PVAT from the
HF+CONT and HF+IT groups. HF coronary PVAT secreted greater interleukin-6
(IL-6) and IL-8 compared to CON which was prevented by both continuous and
interval exercise training regimens. We conclude chronic continuous and interval
exercise is a potential therapeutic strategy to prevent coronary artery stiffness via
inhibition of PVAT-derived AGE secretion in a pre-clinical mini-swine model of
pressure overload-induced HF.

Key Words: advanced glycation end products, perivascular adipose,
inflammation, oxidative stress
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CHAPTERⅠ
Introduction
Stiffening of the large elastic arteries is an independent predictor of
cardiovascular events, promotes hypertension, and is associated with incident
heart failure (HF) [1]. HF is defined as dysfunction of ventricular blood filling or
ejection due to any structural or functional impairment of the heart. [2] The two
types of HF are HF with reduced ejection fraction (HFrEF) and HF with preserved
ejection fraction (HFpEF). HFpEF compromises almost 50% of HF patients [2]. In
addition, no therapy has been shown to improve the survival rate in randomized
control trial with HFpEF [3]. The increased afterload due to aortic stiffening and
augmented pulse pressure contributes to the failure of the myocardium [4].
Recently, our laboratory reported increased coronary artery stiffness in an aorticbanded mini-swine model of pressure overload-induced HF [5], indicating the
increased afterload also promotes coronary vascular dysfunction. Therefore,
identifying mechanisms and interventions to reduce coronary artery stiffness may
also alleviate additional stress on an already failing myocardium.
A key characteristic of arterial stiffening is remodeling of the extracellular
matrix (ECM) within the vasculature. More specifically, reductions in elastin,
increased collagen and a greater abundance of advanced glycation end products
(AGE) collectively promote vascular stiffening [6]. AGE decreases arterial elastin
and cross-links ECM proteins, in addition to influencing the artery through the
receptor of AGE (RAGE)-mediated cellular signaling mechanisms [7]. Arterial
AGE accumulation occurs in conditions where plasma glucose is elevated, such
as diabetes. However, adipose tissue in non-diabetic conditions has also been
1

shown to secrete AGE [7]. Perivascular adipose tissue (PVAT) is an endocrine
tissue shown to promote arterial dysfunction, including arterial stiffness [8, 9].
These findings are significant as recent evidence has shown PVAT surrounding
the coronary arteries, which is associated with increased inflammation, predicts
cardiac mortality [10]. Notably, both aging and HF promote PVAT oxidative stress
and inflammation, which are important factors for AGE production in adipose
tissue, suggesting PVAT may be a novel source of AGE contributing to arterial
stiffness [5, 9, 11]. Currently, however, it is unknown if PVAT secretes AGE to
promote arterial stiffening with HF.
Both chronic continuous and interval exercise training programs are
effective at reducing blood pressure and de-stiffening large elastic arteries such
as the aorta [12, 13]. However, the influence of exercise training on other conduit
arteries, such as the carotid artery, is controversial. Continuous exercise training
for 16-weeks did not decrease carotid artery stiffness in HFpEF patients [14].
While 16-weeks interval training prevented carotid artery stiffness of HFpEF miniswine [15]. Thus, these data suggest interval exercise training may have greater
beneficial effects on carotid artery stiffness compared to continuous exercise
training. However, little is known about the efficacy of chronic continuous and
interval exercise to prevent coronary artery stiffening in a translational large
animal HF model.
The mechanisms by which exercise prevents and/or reverses central
(aorta and carotid) arterial stiffness have been attributed to maintaining elastin
and lowering collagen content [16-18], while suppressing oxidative stress and
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inflammation [19]. Importantly, non-exercise interventions that reduce PVAT
oxidative stress, inflammation and AGE accumulation are associated with
reductions in aortic stiffness [20]. These findings collectively suggest exercise
may prevent coronary artery stiffness by lowering PVAT-related AGE secretion.
The aim of this study was to determine the influence of both chronic
continuous and interval exercise training on PVAT-related AGE secretion to
promote coronary artery stiffness in a pre-clinical mini-swine model of pressure
overload-induced HF. We hypothesize both continuous and interval exercise
training will prevent coronary artery stiffness associated with ECM remodeling,
AGE accumulation, oxidative stress and inflammation through a mechanism
mediated by PVAT-related AGE secretion. We also hypothesize the beneficial
effects of the interval exercise regimen will be greater than the continuous
exercise program.

CHAPTERⅡ
Review of literature

Cardiovascular disease (CVD) is the leading cause of death in the United
States and has a serious financial burden on national health care [21-23].
According to an American Heart Association (AHA) statement, 40.5% of the U.S.
population is predicted to have some form of CVD and the medical cost
estimation is expected to be $818 billion by 2030 [24]. CVD is referred to
coronary artery disease, atherosclerosis, heart failure, hypertension, arterial
stiffness, and other heart or blood vessel-related disease [25, 26]. Specifically,
3

arterial stiffness is associated with myocardial infarction and stroke which are the
two leading causes of death in the developed world [27]. Aortic pulse wave
velocity (aPWV) is the gold standard measurement of arterial stiffness in clinical
settings. Importantly, aPWV is considered a strong predictor of mortality due to
cardiovascular-related events and all-cause mortality [28-31]. Thus, it is of great
importance to understand the mechanisms of arterial stiffness to develop
potential treatment strategies.

Arterial stiffness
Definition
The most recent description of arterial stiffness is the reduced buffering
capacity of arteries which is associated with decreased elasticity of the vascular
wall [32, 33]. To better explain arterial stiffness, several models have been
developed [34]. One of them is the Windkessel model [35] which describes the
arterial system like a fire-hose system. The inverted air-filled dome, referred to
large artery, was used to buffer the blood flow. The wide-bore hose was the
conduit vessel. The fire hose nozzle was the peripheral artery/resistance [1].
However, elastic artery serves both “conduit” and “cushioning” functions. The
Windkessel model ignores the “conduit” compliance while only focus on the
peripheral resistance.
Artery compliance (C) was first proposed by Spencer and Denison in 1963
[36]. When given a certain amount of pressure to an artery, the degree of vessel
volume change is termed as compliance [37]. The compliance can be calculated
as C=ΔV/ΔP, where ΔV and ΔP are the volume and pressure changes in a
4

cardiac cycle during systole and diastole. Elastance is the reciprocal of
compliance. Thus, stiffness can be quantified by elastic modulus/Young’s
modulus [38]. Compared to the Windkessel model, elastic modulus covers the
elastic properties (elastin and collagen region) of the arterial wall [1]. Thus,
arterial stiffness can be also defined as an artery with a reduced capacity to
expand or recoil during the cardiac cycle. The above explanation of arterial
stiffness is focused on the arterial wall component alterations, the two primary
proteins collagen and elastin [39]. However, the factors contributing to arterial
stiffness are not limited to collagen or elastin.

Measurement of arterial stiffness
Aortic pulse wave velocity (aPWV)
The aorta is the largest artery that contributes buffering effects to
modulate blood pressure and maintain consistent blood flow to peripheral ends
[32, 40-43]. Aortic stiffness affects blood pressure and blood flow. In addition,
aortic stiffness is an independent predictor of CV events [28, 30, 44-47]. The
most common and non-invasive clinical measurement of arterial stiffness is aortic
pulse wave velocity (aPWV), which measures the pulse wave as it travels from
carotid artery to femoral artery. Currently, pressure sensors (tonometer) which
captures the wave form from pulse wave is a reliable and reproducible method to
assess pulse wave velocity [48]. The PWV measurement system detects the time
delay (Δt) between the feet of the two waveforms and records distance from
carotid artery to femoral artery (D) [49, 50]. Then aPWV is calculated as D/Δt
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[51]. Normal reference of aPWV value is about 6.2 m/s in less than 30 years old
population and about 10.9 m/s in older than 70 years old population [52].
While aPWV is the gold standard assessment of arterial stiffness, this
method does have disadvantages. The distance is measured on the body
surface with a measurement tape by the investigator. In actuality, measured
distance is an estimation over the true distance and is largely dependent on body
shape [53]. Thus, systematic error in PWV estimation is dependent on distance
measurement. To minimize the distance measurement error, some investigators
recommend: 1) subtracting the distance from the carotid location to the sternal
notch from the total distance or 2) subtracting the distance from the carotid
location to the sternal notch from the distance between the sternal notch and the
femoral site of measurement [50, 54]. In addition, heart rate and blood pressure
are important confounders of PWV assessment. It has been shown that PWV
increases with elevated blood pressure and increased heart rates [55, 56]. To
minimize the blood pressure and heart rate influences, it is recommended that
measurements be acquired in a quiet room with a minimal resting period of 10
minutes with no smoking, meals, alcohol, and beverage containing caffeine at
least 4 hours prior to measurement [54].

Pulse wave analysis
Pulse wave analysis is a measurement that allows the accurate recording
of peripheral pressure waveforms and the corresponding central waveform used
to assess central hemodynamic parameters [57]. The SphygmoCor system
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(AtCor Medical, Australia) is one of the most widely used devices to estimate
central blood pressure which is correlated well with invasive catheter
measurements of aortic blood pressure [58, 59]. The system can generate
central hemodynamic parameters: systolic and diastolic pressure, average aortic
hemodynamic pressure, aortic pulse pressure, augmentation index (AIx) [60].

Central pulse pressure
Central pulse pressure is the difference between systolic pressure and
diastolic pressure which is an important marker of arterial stiffness. Central pulse
pressure has two determinants: 1) ventricular ejection interacting with the
viscoelastic properties of the aorta; and 2) wave reflection, or return wave from
the distal site to heart [32, 61, 62]. Thus, increased arterial stiffness is associated
with increased central pulse pressure. Increased pulse pressure is also a
predictor of CV risk in subjects with myocardial infarction and congestive heart
failure [63-65]. In addition, using pulse pressure to predict the risk of coronary
heart disease is better than using systolic or diastolic pressure in middle-aged
and elderly adults [66]. These findings demonstrate the central pulse pressure
could be an important pathological index in clinical settings.

Augmentation index (AIx)
AIx is calculated as the difference in height between the first and second
systolic peaks (augmentation pressure [AP]) in the aortic waveform which is
expressed as a percentage of aortic pulse pressure: AP/PP *100% [67]. The
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determinants of AIx is wave reflection during each cardiac cycle. Wave reflection
is influenced by three major factors: 1) the distance to the reflecting site; 2) the
speed of wave transmission, and 3) the magnitude of the reflection coefficient
[68]. With increased PWV, the reflected wave arrives back to left ventricle earlier
during diastole. Then the reflection wave leads to a secondary systolic pressure
peak and increases central pulse pressure [68]. Previous research indicated that
AIx is correlated with PWV in middle-aged men and women [69]. Thus, AIx could
potentially serve as a predictor of CV events. As such, AIx is an independent risk
factor for premature coronary artery disease in young subjects [70]. However,
previous Framingham Heart Study showed that AIx increased in middle-aged
individuals and then plateaued (in men) or declined (in women) beyond 60 years
of age while aPWV continued to increase [71]. Furthermore, AIx was not
associated with increased aPWV in patients with diabetes and during betaadrenergic stimulation [72-74]. Therefore, additional consideration should be
taken when using AIx as an assessment of arterial stiffness in special population
groups.

Ex vivo mechanical testing
Although arteries share the same three layers which are the tunica intima,
tunica media and tunica external (adventitial), the histological structure and
composition of the arterial wall differs as does the function. [75]. In human
beings, vessels more than 10 mm in diameter are typically considered elastic
arteries. As such, the aorta is a large elastic artery that contains a high
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percentage of elastic fibers in three layers. The elastic fibers allow the aorta to
expand or recoil to maintain stable blood pressure and deliver blood to distal
sites. Arteries with diameters between 0.1mm to 10mm are typically considered
muscular arteries. Muscular arteries have fewer elastic fibers, which results in
less ability to expand or recoil, and their major function is to distribute the blood
to capillaries. Arteries with diameters less than 0.1mm are typically arterioles and
function to provide resistance. Arterial stiffness assessed by PWV is quite
different between these different arteries due to differences in wall structural
components. The human coronary arteries are muscular arteries with an average
diameter about 4mm, about 10-13 cm in length of the left anterior descending
artery and 12-14 cm in length of the right coronary artery [76]. Because the
length of the coronary artery is shorter, errors in assessing distance
measurement will result in a larger mistake in calculating PWV. Therefore, PWV
is not an ideal method to assess coronary artery stiffness in vivo.
The most common and easiest ex vivo mechanical test used to quantify
arterial stiffness in the laboratory is the uniaxial tensile testing [77]. In this
procedure an arterial segments are stretched in the horizontal plane at a
constant displacement rate, while the force generated by artery is recorded.
Testing is terminated at a yield point when tissue fails to generate force in
response to increased stretch. The recorded displacement-force data are
converted to a stress-strain curve. According to Young’s Modulus, stiffness is
quantified as the slope of the linear part of the stress-strain curve [77]. The toe
part of the stress-strain curve represents elastin protein effects, which
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responsible for expansion and recoil of the artery. While the heel part of the
curve represents the collagen protein effects, which produces force against
higher pressures. In summary, the most two common arterial stiffness
assessments are PWV and ex vivo mechanical testing. The advantages of PWV
are 1) non-invasive, 2) gold standard in clinical settings and 3) predictor of CV
events. However, it cannot explain the arterial wall structural alterations. The
advantages of mechanical testing are 1) application to all arteries and 2)
explanation of the vascular wall component changes, but requires acquisition of
arterial samples.
In this research project, the coronary artery stiffness was assessed by ex
vivo mechanical testing with a Myograph (DMT 620, Denmark). The simplified
description of the Stress-Strain curve is shown as Figure 2-1.
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Figure. 2- 1 Ex vivo mechanical testing

Importance of arterial stiffness
Arterial stiffness is a strong predictor of not only CVD-related mortality, but
also all-cause mortality. Particularly, increased aPWV has been shown as an
independent predictor of coronary artery disease and stroke over a 10 year
follow-up [78]. More studies have elucidated the importance of arterial stiffness.
The estimation of myocardial infarction, unstable angina, heart failure or stroke is
approximately twice in subjects with higher aPWV compared to subjects with a
lower aPWV [79]. Another study conducted in well-functioning elders showed that
higher aortic PWV was associated with CVD mortality and other disease mortality
11

[28]. A population-based study also showed that arterial stiffness is strongly
associated with lipid plaques at various arterial tree sites [80]. An investigation on
end-stage renal disease patients demonstrated that elevated aortic elastic
modulus was associated with an increased hazard ratio of cardiovascular and allcause mortality [81]. Importantly, angiotensin-converting enzyme inhibitor
treatment on renal dysfunction patients increased survival rate associated with
reduced arterial stiffness independent of blood pressure changes [82]. This study
may suggest that, compared to blood pressure alone, arterial stiffness is more
tightly related to survival in renal dysfunction patients.
In general, healthy arteries expand and recoil during systole and diastole.
The elastic properties of large arteries tends to decrease with aging and disease.
Prevention strategies and treatments of arterial stiffness are critical to reduce
CVD-related events and all-cause mortality. Thus, to understand the
mechanisms of arterial stiffness is essential to support prevention and
therapeutic strategies to lower CVD risk.

Contributors to arterial stiffness
Stiff arteries lose the elastic properties which is associated with vascular
wall remodeling. Arterial stiffness is involved with complicated reactions at the
cellular and molecular levels. These vasculature alterations are affected by blood
flow shear force and extrinsic factors such as advanced glycation end products
(AGE), oxidative stress, inflammatory response and metabolic dysfunctions of
glucose and lipid.

12

Collagen and Elastin
Collagen and elastin are the two major scaffolding proteins which provide
compliance, elasticity, and stability to the vascular wall [83]. Collagen is the most
abundant protein in humans and is the main component of connective tissue [84].
The most abundant collagen subtypes in the normal human artery are type I (7075%), type III (20-25%) and type V (1-2%) [85]. Type I and type III collagens are
the major components of the three vessel layers, while type IV (comprise more
than 90% of the total protein of the basal lamina) and type V collagens are in the
basement membrane of smooth muscle cells of the intima and medial layers [86,
87]. Elastin is the other major extracellular matrix (ECM) protein of large arteries
with characteristics of extensibility and elasticity [88]. Elastin formation is limited
to the embryo stage and infancy [89]. Therefore, elastin content is greatest at
birth and progressively decreases with aging. Accelerated elastin degradation
and fragmentation due to some disease conditions will result in premature arterial
stiffening [90].
The production and degradation of collagen and elastin are in balance in
healthy conditions. Dysregulation of the balance caused by overexpression of
abnormal collagen and degradation of normal elastin promotes vascular stiffness
[6]. Increased collagen type I is associated with myocardial fibrosis in
hypertensive heart disease patients. Another report shows that collagen type I
overproduction is associated with increased aPWV in diabetes with coronary
artery disease [91]. Moreover, in atherosclerotic lesions, type I and III collagens
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are the major structural component while type IV and type V collagens are not
[86]. Heart failure induced by hypertension and diabetes has been shown to
stimulate excessive collagen production [92, 93]. Histological analyses of
stiffened vessels indicate that the ratio of collagen to elastin was increased [94].

Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs
Collagen and elastin comprise a large portion of ECM and are regulated
by matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) [95].
MMP are responsible for extracellular matrix degradation. Different MMPs
subunits have different functions [96]. MMP-1 degrades types I, II, and III
collagen; MMP-2 degrades type IV collagen and elastin; MMP-3 degrades
laminin, fibronectin, elastin, gelatin, and proteoglycans, and MMP-9 degrades
type IV collagen and elastin. A recent publication reported that increased MMP-2
and 9 levels were greater in hypertensive subjects and positively related to PWV
[97]. Another study showed that deficiency of MMP-9 and MMP-12 protected
ApoE -/- mice from atherosclerosis [98]. Moreover, MMP-1 was positively
correlated with aPWV in both normotensive and hypertensive subjects [99].
The TIMP family is comprised of four MMP inhibitors: TIMP-1, 2, 3 and 4
[100]. A human study indicated that plasma TIMP-1 level was increased in
hypertensive subjects [101]. An animal study demonstrated that hypertension
induced by angiotensin II was prevented in TIMP 3-/- mice that had reduced
collagen and elastin content in both the carotid and mesenteric arteries [102].
This finding shows that TIMP 3-/- has a preventative effect in hypertension but
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with an adverse remodeling in the extracellular matrix. MMPs expression is also
regulated by other cellular factors like, increased pro-inflammatory, cytokines,
and oxidative stress which promote MMPs to induce less effective collagen and
fragment elastin which in turn promotes vascular stiffness [103-105].

Advanced glycation end products (AGE)
Advanced glycation end products (AGE) are complex and heterogeneous
groups of molecules which are associated with diabetes, cardiovascular disease,
Alzheimer’s disease and end stage renal disease [7].

AGE formation
Reducing sugars react with proteins, lipids, and nucleic acids following
glycation, oxidation and/or carboxylation to produce AGE [7, 106]. In general, the
highly reactive glucose aldehyde group with the amino group of proteins produce
a Schiff’s base, which spontaneously rearranges itself into an Amadori’s product.
After continued modifications Amadori’s product becomes AGE. In addition,
some highly reactive carbonyl agents like glyoxal and methyl-glyoxal can be
produced by oxidized glucose, Schiff’s base and then Amadori’s product will
react with free amino groups to form N-q-carboxy-methyl-lysine (CML). The slow
extracellular glycoxidation reaction which produces CML [107] ranges from
weeks to months, thus long-lived proteins, such as collagen are primary targets
[108]. The major AGE chemical structures are: 2-(2-furoyl)-4(5)-furanyl-1H-
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imidazole (FFI), 1-alkyl-2-formyl-3,4-diglycosyl pyrroles (AFGPs), N-ε-carboxymethyl-lysine (CML), pyrraline and pentosidine [109].
Greater AGE concentrations are usually associated with increased plasma
glucose and renal dysfunction [7]. AGE concentration was increased after a few
weeks when animals had increased plasma glucose [110]. Compared to the
normal conditions, circulating AGE increased approximately two fold in diabetic
animals [111]. Since small soluble AGE peptides are cleared in the kidney, renal
dysfunction contributes to AGE accumulation and leads to vascular disease
[112]. Further, diabetic patients with end stage renal disease (ESRD) had up to
100 fold circulating AGE compared to diabetics with normal renal function
patients [113, 114].
Lipids are involved in the glycation process as well. Quick lipid
peroxidation with reactive oxygen species (ROS) produces free AGE or protein
bound AGE in both intracellular and extracellular spaces [115, 116]. AGE
reduces paraoxonase activity by 40% in type II diabetes and coronary artery
disease patients [117] which in turn induces oxidized low-density lipoprotein
(LDL) accumulation. In our previous study, we found AGE accumulated in the
aorta with elevated plasma LDL [8]. In addition to the endogenous formation,
AGE could also be accumulated in blood by food absorption [118, 119]. Plasma
AGE level is related to aortic stiffness independent of age and blood pressure
[120]. This finding indicates that adipose tissue is a potential source of AGE.
AGE effects in cellular and molecular levels
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The pathogenic influence of AGE are via two different pathways. First,
AGE form cross-links with proteins that results in an irreversible process which
alters protein structures and functions [112]. Specifically, AGE cross-linking with
type I collagen changes the protein structure [121]. AGE can form cross-links
with collagen IV on the basement membrane to prevent normal network-like
structures as well [122]. Increased stiffness in the vasculature and other tissues
due to pathological alterations by AGE-collagen cross-link formation is common
in diabetic and aging conditions [123].
AGE can also form cross-links with LDL through three-dimensional
structural changes, which in turn, prevented recognition by cellular LDL receptor
[124]. In addition, excessive AGE increases LDL susceptibility to oxidative
modifications to promote oxidized LDL formation [125]. The oxidized LDL can
react with free amino groups of proteins to form AGE products, including CML,
CEL and others [126, 127].
In older mice, the increased aortic stiffness has been shown to be
associated with less elastin per mm2 of the vascular wall by AGE-elastin
formation [128]. In addition, exogenous AGE administered to rodents promotes
elastin disruption and fragmentation that is associated with arterial stiffness [129].
Previous research has indicated that cross-linking collagen promotes myocardial
stiffness and cardiac chamber remodeling in hypertensive heart disease. In
detail, spontaneously hypertensive rats had a decrease in soluble myocardial
collagen concomitant with an increases in cross-linked myocardial collagen
which in turn promoted the myocardial stiffness [130]. A histological study
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conducted on human aorta illustrated a correlation between AGE accumulation
and aortic stiffness, which is assessed by ex vivo mechanical testing [131-133].
Currently, adequate evidence supports the notion that collagen cross-linking is
an important mechanism of decreased vascular and cardiac compliance.
Second, AGE binds to a cell membrane receptor to stimulate AGE related
signaling. AGE have several receptors, the receptor for AGE (RAGE) is the most
well characterized AGE receptor [134]. RAGE expression is increased in the
blood and kidneys in those with diabetics compared to control [135]. RAGE has
also been found on endothelial cells, specifically in the area of atherosclerosis
[135]. In vitro investigations demonstrated that increased oxidative stress and
activation of the Nuclear factor-kappa B (NF-κB) signaling was associated with
AGE-RAGE binding on macrophage cells [136, 137]. We recently reported that
the greater AGE accumulation in the vascular wall was associated with increased
oxidative stress and NF-kB p65 subunit expression through RAGE expression
was unchanged with HF [5].
AGE has been shown to increase intracellular oxidative stress. A previous
study indicated that endothelial cells cultured with AGE increased thiobarbituric
acid reactive substances, a byproduct of lipid peroxidation, and heme oxygenase
mRNA expression [136]. Moreover, human endothelial cells cultured with AGE
prompted intracellular generation of hydrogen peroxide and was prevented by
soluble AGE, which blocks the RAGE receptor [138]. Further, AGE have been
shown anti-oxidant properties resulting in a reduction of glutathione, vitamin C
and nitric oxide leading to reduced vasodilation [139]. AGE accumulate in pro-
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inflammatory sites and promote atherosclerotic lesions in non-diabetes as well
[140]. A previous study showed that activated NF-kB induced by AGE released
interleukin-1 (IL-1), IL-6 and TNF-a [141], in which IL-6 has been shown as a
contributing factor to aortic stiffness [8]. Moreover, the AGE–RAGE mediated
cellular signaling includes multiple intracellular signal transduction pathways like
p21ras, mitogen-activated protein (MAP) kinases, Phosphoinositide 3 (PI3)
kinase, cdc42/rac, Jak/STAT, NAD(P)H oxidase [138, 139, 142-146]
In summary, excessive AGE accumulation increases oxidative stress and
inflammatory response leading to arterial stiffness, while the pathological
changes are accelerated in diabetic and aging conditions [147].

Treatment targeting AGE
Therapeutic interventions focused on AGE formation, AGE cross-linking
and AGE–RAGE interaction have been investigated. Aminoguanidine (AMG) is
the first AGE inhibitor which functioned as nucleophilic hydrazine compound to
prevent Amadori's products that react with proteins to form AGE [148]. AMG
prevented albumin to form AGE with glucose and AGE cross-linking of collagen
[148]. Evidence also demonstrated that AMG preserved arterial elasticity through
inhibition of collagen cross-linking [149]. Further, AMG is the most promising
agent which reduces the heart AGE levels, RAGE levels and collagen expression
[150]. In addition, AMG reduces AGE accumulation absorbed from food [151].
Another agent was developed to remove the irreversibly bound AGE from
connective tissues and matrix components [152]. Alagebrium chloride (ALT-711)
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is a cross-link breaker compound which has been shown to decrease pulse
pressure in elderly adults with vascular stiffening [153]. ALT-711 decreased large
artery stiffness that was associated with reduced collagen deposition and
attenuates left ventricle stiffness in diabetic and aging animal models [154, 155].
The development of AGE cross-link breakers may be a potential target for future
therapy of isolated systolic hypertension and diastolic heart failure [123].
As mentioned above, AGE-RAGE mediated downstream cellular signaling
promotes oxidative stress and inflammatory responses. This may suggest that
interference with the AGE-RAGE interaction would interrupt or stop related
cellular activation, and consequently ameliorate various chronic disorders [156,
157]. RAGE mRNA has two major truncated forms: N-terminal and C-terminal
[158] which are named soluble RAGE. Soluble RAGE has been reported to
dramatically reduce AGE accumulation and improve vascular function [159]. In
addition, the administration of soluble RAGE to diabetic mice showed that
inflammatory cells, mRNA levels of glomerular cytokines and extracellular matrix
were decreased, which in turn reduced vascular lesion area and complexity [160,
161].
Insulin has also been proposed to contribute in AGE elimination through
PI3-kinase pathway associated with nitric oxide production and resulting in
vascular protective effects [162, 163]. This finding suggests activation of PI3kinase not only promotes glucose metabolism but also AGE metabolism. In
addition, the anti-oxidant agents Vitamin C, has been reported to prevent the
oxidative conversion during AGE formation [164].
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In summary AGE and AGE-mediated cellular signaling promote
vasculature dysfunction and wall remodeling through cross-linking formation,
oxidative stress, and inflammation. Comprehensive understanding of the
mechanisms of AGE formation and regulated activity is critical to control or
prevent cardiovascular disease.

Oxidative stress
Oxidative stress source
Oxidative stress is an imbalance between the overproduction of reactive
oxygen species (ROS) and reduced antioxidant defenses [165, 166]. ROS are
reactive chemicals with oxygen such as peroxides, superoxide, hydroxyl radical
and single oxygen [167]. The major source of ROS comes from mitochondria
where oxygen leaks during oxidative phosphorylation [168]. Mitochondrial DNA
damage is greater in atherosclerotic human arteries compared to normal human
arteries, in part, due to oxidative stress [169]. Mitochondrial DNA encodes
portions of the electron transport chain [170], thus damage on mitochondrial DNA
may cause more ROS leaking from mitochondria associated with structural
damage. Mitochondria ROS are also regulated by mitochondria membrane
potential, O2 concentration, nuclear transcription factors, and cytokines [171].
Peroxynitrite is another ROS compound resulting from the reaction of
superoxide and nitric oxide along with increased oxidative stress [172].
Peroxynitrite oxidizes lipoproteins and nitrate tyrosine residues in many proteins
[173]. Since the production of peroxynitrite is difficult to assess, nitrosylation of
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proteins have been considered as an indirect biological marker of oxidative
stress [174]. Though nitrotyrosine is not detectable in the plasma of normal
healthy subjects [175], the circulating nitrotyrosine concentrations are detectable
and associated with cardiovascular disease [176].

Oxidative stress influences on cellular dysfunction
Increased ROS stimulates a pro-inflammation response and activates NFκB related signaling [171, 177]. One previous study indicated that cells treated
with agents that restored ROS prevents protein kinase C, AGE accumulation and
NF-kB activation [178]. Activation of NACHT, LRR and PYD domains-containing
protein 3 (NALP3) will trigger an inflammatory response, which is positively
regulated by ROS [179, 180]. Recent studies showed that excessive ROS had an
adverse effects on vascular function associated with cellular protein damage and
an overall reduction in bioavailable endothelium-derived nitric oxide [181].
Moreover, reduced ROS accumulation decreased IL-6 production induced by
endotoxin lipopolysaccharide [177]. Reduced IL-8 expression is associated with
ROS inhibition in human aortic endothelial cells in vitro [182]. Several studies
showed that excessive ROS accelerates atherosclerosis lesion formation.
Deficiency of SOD2, a mitochondria-specific antioxidant enzyme, in
apolipoprotein E-/- mice contributes to atherogenesis at arterial branching points
[169]. Also, oxidative stress has been shown to dramatically increase in aorticbanded guinea pigs and is reduced by Vitamin E therapy [183]. However, clinical
use of Vitamin E to prevent oxidative stress has not shown beneficial effects on
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mortality compared to the control group [184]. Another long-term study showed
that neither vitamin E nor vitamin C supplementation reduced risk of major
cardiovascular events [185].
Oxidative stress has been shown to mediate collagen and collagen-related
signaling. One study indicated that oxidative stress mediated the collagen type I
expression and activation of NF-kB in vitro [186]. Another experiment showed
that exposure to oxidative stress stimulated MMP expression and influenced the
vascular remodeling [187].
Oxidative stress could influence vascular function by endothelial cells.
Substantial evidence suggests that atherosclerotic lesion formation is associated
with oxidative stress [188]. Another study shows that high blood glucose
increases ROS, NF-κB activation, upregulation of endothelial cell adhesion
molecules intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), trans-endothelial migration of monocytes, and monocyteendothelial adhesion in human coronary artery endothelial cells (140). In
addition, over expression of thioredoxin-2 (Trx2), a mitochondrial antioxidant
enzyme, attenuated endothelial function and prevented atherosclerotic lesions in
ApoE-/- mice, which was associated with decreased oxidative stress and elevated
NO bioavailability [189]. The above evidence suggests that attenuated oxidative
stress protects the vasculature.
In summary, oxidative stress has been recognized as a crucial factor to
vascular diseases and atherosclerosis development. Long-term studies have
indicated that oxidative stress is a strong predictor of cardiovascular events in
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coronary artery disease patients [190] and is strongly associated with arterial
stiffness measured by PWV [191]. Thus, it is of importance to investigate the
oxidative stress-related mechanisms of arterial stiffness in order to develop
effective therapeutics.

Inflammation
Inflammation is part of biological responses to local injury [192]. The
stimulated inflammatory response produces cytokines such as IL-1β, IL-6, tumor
necrosis factor-α (TNF-α) [193, 194], and activates the NF-κB pathway [195]. Creactive protein (CRP), an inflammation marker, has a direct role in promoting
inflammatory response on human aortic endothelial cells which is associated with
reduced antioxidant defense [196, 197]. Previous studies have shown that
reduction of inflammation (CRP) reduced aPWV [198]. It suggests that CRP
inhibition may decrease PWV. Moreover, arterial stiffness measured by aPWV is
associated with inflammation-related signaling such as IL-6, TNF-α and CRP
[199]. Another in vitro study indicated that inflammation promoted arterial
stiffness associated with vascular wall remodeling through activated mitogenactivated protein kinases (MAPK) p38 controlled gene [200]. As mentioned in the
“Oxidative Stress” section, angiotensin II increase ROS production and
stimulates MMP expression through the expression of active transforming growth
factor-β (TGF-β) [201] leading to vascular wall remodeling [202]. Another study
suggested that macrophage, CD68, angiotensin II related proteins and enzymes
activity were increased in older human thoracic aorta compared to young adults.
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The pathological alterations with inflammation increased vascular wall thickness
[203]. Also, monocyte chemoattractant protein-1/C-C chemokine receptor type 2
(MCP-1/CCR2) pathway has an important role in arterial inflammation to induce
IL-1 and IL-6 expression [204] which resulted in vascular remodeling and left
ventricular hypertrophy [205]. MCP-1 induces vascular smooth muscle cell
proliferation and activates NF-kB signaling [206]. In summary, substantial
evidence demonstrates that inflammation influences arterial stiffness, suggesting
treatments targeting reductions in the inflammatory response will prevent arterial
stiffness.

Perivascular adipose tissue (PVAT)
PVAT characteristics
In the past decade, much interest has been focused on adipose tissue,
which surrounds the blood vessels. Recent investigations have demonstrated
that PVAT is an endocrine tissue and can transfer signals to adjacent blood
vessels [207]. There is no fascial layer or elastic lamina between PVAT and the
vasculature, where PVAT interlaces with the adventitial layer [208, 209]. In
addition, the vasa vasorum within PVAT proliferates when inflammation and
injury occurrs [210-212], resulting in the release of mediators from PVAT to the
vascular system. The vasa vasorum are tiny blood vessels which supply blood to
the outer layers of the artery [213]. Secretomes from PVAT are different from
visceral and subcutaneous adipose tissue [214]. Thus, these characteristics
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suggest that PVAT may have a unique role in influencing the vasculature [215,
216].

PVAT and cytokines
One of the key features of PVAT is regulation of inflammation. Cytokines
like IL-6, IL-8, leptin, MCP-1, and resistin released from PVAT induces
endothelial cell dysfunction, increases oxidative stress, and causes smooth
muscle cell proliferation and migration [217-219]. One recent study demonstrated
that inflammatory cells were increased in PVAT surrounding the atherosclerotic
aorta compared to the normal aorta [220]. Other similar studies revealed that
mRNA and protein concentrations of IL-1β, IL-6, MCP-1, and TNF-α were
elevated and adiponectin protein level was lower in PVAT diseased coronary
arteries [221, 222]. Wild type mouse aorta cultured with LDL receptor-/- PVAT
which secreted greater IL-6, promoted aortic stiffness [8]. Another animal study
indicated that IL-8, IL-6 and MCP-1 mRNA level and protein expressions were
higher in PVAT compared to peri-renal and subcutaneous adipose tissue [208],
thus confirming PVAT’s specific role in inflammatory responses. Another
research investigation reported that adrenomedullin which was a vasodilator and
anti-oxidative peptide was expressed in epicardial adipose tissue [223]. Thus,
PVAT released pro-inflammatory cytokines may serve as a protective mediator.
Recent studies reported that epicardial adipose tissue size was positively
related to coronary artery disease, which was associated with insulin resistance
and inflammation [224-227]. However, the influence of PVAT on the vasculature
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is not completely understood. Yudkin et al. proposed a “vasocrine” model in that
cytokines were directly released from PVAT to the vasculature, and thereby
regulated vascular function [228]. The above studies proposed that mediators
from PVAT were directly released into adjacent blood vessels. PVAT has been
shown to affect smooth muscle cells as well. Animal studies have showed that
PVAT releases cytokines which stimulated smooth muscle cell proliferation [218].
Conditioned media from cultured PVAT of aging and obese rats promotes human
aortic smooth muscle cell proliferation [229]. In summary, cytokines released
from PVAT contributes to vasculature modifications, but the mechanism is still
not understood.

PVAT and oxidative stress
Another feature of PVAT is promoting oxidative stress. Animal study
showed that mice with characteristics of metabolic syndrome had mesenteric
artery remodeling associated with increased superoxide production and NADPH
oxidase activity in PVAT [230]. A similar study concluded that diet induced obese
mice had vascular endothelial dysfunction and an increased pro-inflammatory
response associated with increased oxidative stress in PVAT [231]. To confirm
that oxidative stress promotes aortic stiffness, PVAT from old mice was
transplanted into healthy young mice which increased PWV and decreased
elastic modulus. In addition, the increased stiffness was abolished by 4-Hydroxy2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL), a superoxide scavenger [232]. In
summary, substantial published research supports the role for PVAT as an

27

important regulator of inflammatory responses and oxidative stress. Thus, PVAT
may be potential novel therapeutic target for improving coronary artery stiffness.

Hypertension and arterial stiffness
Blood pressure is an important physiological and pathological predictor of
cardiovascular events [32]. Previous studies have shown that patients with
isolated hypertension have higher aPWV [233]. In addition, a large population
study indicated that higher aortic stiffness was associated with an increased risk
of incident hypertension [234]. These findings revealed the connection between
arterial stiffness and hypertension. However, it is controversial which comes first:
arterial stiffness or hypertension [235]. One theory is that vascular wall stiffness
precedes elevated blood pressure resulting in hypertension. Obese mice fed a
diet of high fat and high sucrose showed increased aPWV within 1 to 2 months
which preceded development of hypertension at 5 months [236]. An alternative
theory is that elevated blood pressure precedes vascular wall alterations:
hypertension deteriorates vascular wall pathology changes leading to stiffer
arteries [237]. This long-term study revealed that hypertension exacerbated
aortic stiffness. Moreover, individuals with well-controlled blood pressure had
less progression of arterial stiffening assessed by aPWV than individuals poorly
controlled blood pressure [238]. Recently, numerous studies investigated the
cellular and molecular mechanisms of arterial stiffening and its relationship with
the development of hypertension. The elastin knockout (Eln−/−) mouse model has
greater arterial stiffening than wild- type mice. Until postnatal day 1, the blood
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pressure in Eln−/− mouse was about twice that of wild-type, and the aortic
stiffness was further increased. Eln+/- mouse had increased arterial stiffness by
postnatal day 7, whereas systolic blood pressure increased until postnatal day 14
[239].
Treatments for hypertension have been shown to work for attenuation of
arterial stiffness. Anti-hypertension drugs targeting the renin-angiotensin system
and aldosterone have been shown to prevent arterial stiffness associated with
decreased collagen accumulation [240]. However, isoflavones, compounds with
antioxidant properties, [241] reduced arterial stiffness associated with
suppressed vascular cell adhesion molecule-1 level but did not affect blood
pressure [242]. In summary, it is important to better understand the association of
arterial stiffness and hypertension.

Aging and arterial stiffness
Aging is defined as the age-related reduction in physiological functions
essential for survival and fertility [243]. It is well established that aging is
associated with increased aortic stiffness [244]. Moreover, age-related changes
in vascular structure and function increase the risk of CVD [245].

Age-related metabolic syndrome promotes arterial stiffness
The risk of acquiring metabolic syndrome components, such as obesity,
dyslipidemia, insulin resistance, and hyperglycemia, increases with aging.
Substantial evidence indicates that aging related metabolic syndrome promotes
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arterial stiffness and accelerates the development of hypertension [246-249]. In
particular, diabetes and dyslipidemia leads to endothelial dysfunction, increased
oxidative stress and inflammation leading to arterial stiffening [243]. Metabolic
syndrome also interacts with inflammatory responses [250, 251]. Therefore,
aging promotes activation of inflammatory responses resulting in increased proinflammatory cytokines, which in turn produces more cytokines, resulting in
endothelial dysfunction and increased oxidative stress [252]. The increased
oxidative stress and inflammatory responses collectively contribute to arterial
stiffening.

Aging increases MMPs expression
Aging is also associated with over expression of MMPs to promote elastin
degradation and collagen accumulation [253]. MMP-2 is associated with the
aging process. Over expression of MMP-2 changes the collagen and elastin
ratio, and activates TGF-β signaling. Increased MMP-2 expression promotes
arterial stiffness which was associated with vascular wall remodeling and calcium
content [254]. Inhibition of MMPs prevented age-related arterial inflammation,
which was associated with preservation of elastin, reduction of collagen leading
to prevent high blood pressure [253]. Interestingly, it appears that carotid artery
properties improve with lessening metabolic syndrome severity which suggest
that arterial stiffness may be reversible with metabolic syndrome [248].

Oxidative stress and other factors in aging
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It is evident that oxidative stress occurs with aging. An animal study
showed that superoxide production was increased in the mesenteric artery in
aging rats [255] and NO bioavailability was decreased in aging-related
hypertensive rats [256]. Moreover, recent studies confirmed that aging-related
endothelial dysfunction and oxidative stress promotes vascular wall remodeling
and stiffness [257-259]. Therefore, aging-related oxidative stress promotes
endothelial dysfunction and activation of inflammatory response leading to
vascular remodeling [260-263].
Aging has been shown to induce aldosterone dysregulation, which
contributes to aging-related inflammatory response [264]. Thus, these findings
suggest age-related salt sensitivity may be regulated by inflammation and
contributes to arterial stiffness. It is well known the nervous system is important
in regulating peripheral artery resistance and blood pressure. A recent study
showed increased sympathetic nerve activity in older women contributes to the
development of hypertension but not in young women [265]. Another paper
demonstrated that reduced sympathetic baroreflex sensitivity promotes arterial
stiffness and hypertension in elderly adults [266]. The above findings may
suggest arterial stiffness in aging may be influenced by the nervous system as
well.

Aging genetic influences in CV events
Recent interests have been focused on age-related gene changes in
vascular function and hypertension. Klotho gene is an anti-aging gene which
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extended life span [267]. In mice where the klotho gene is overexpressed,
oxidative stress and insulin resistance were attenuated [267]. Greater expression
of klotho gene also reduced blood pressure and restored kidney damage in
spontaneously hypertensive rats [268]. However, the klotho gene expression
prevented IL-10 production and superoxide production [268]. To confirm the
influence of klotho on blood pressure, another research group showed that klotho
gene deficiency caused salt-sensitive hypertension via CCR2 and MCP-1 [269].
Since arterial stiffness and hypertension are influenced by oxidative stress and
inflammation, it would be logical to predict that anti-aging genes have an
important role in modulating age-related vascular structural and functional
alterations.

Genetic base of arterial stiffness
Arterial stiffness is an independent predictor of cardiovascular mortality
after adjustment for traditional risk factors like age, sex, and mean blood
pressure [44, 45, 270]. Moreover, carotid artery stiffness was greater in
teenagers with a parental history of myocardial infarction or diabetes compared
to the teenager without such parental history [271]. A similar study showed that
offspring had increased AIx in families which had a history of hypertension [272].
Thus, these findings suggest that genetic factors are a potential factor related to
arterial stiffness.

Genetic mutation of elastin and collagen
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Gene mutations in elastin and collagen also contributes to arterial
stiffness. Genetic research on elastin indicated A allele of the Ser422Gly
polymorphism, which is A-to-G nucleotide change, was positively associated with
carotid stiffness [273]. Another study showed genetic mutation of fibrillin-1 is
associated with large artery stiffening and increased pulse pressure in coronary
artery disease patients [274]. In addition, MMP-3 genotyping promoted agingrelated aortic stiffness associated with vascular remodeling [275]. Though some
investigations demonstrated phenotype of some genes promoting arterial
stiffness, the underlying signaling pathway is not well understood.

Genetic mutation of renin-angiotensin system
Genotype-phenotype studies focused on the renin-angiotensin system
showed that angiotensin II type 1 receptor gene polymorphism was correlated
with aortic stiffness [276]. Another large population research concluded that
angiotensin II type 1 receptor genotype could influence arterial stiffness in aging
hypertensive patients [277]. A similar study performed in hypertensive patients
and genotyped mice showed that angiotensinogen gene is a genetic marker for
arterial stiffness, whereas in genotyped mice with high concentration of
angiotensinogen had increased arterial stiffening [278]. These data reinforce that
renin-angiotensin system is another key factor in arterial stiffness.

Heart failure and coronary artery disease
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Heart failure (HF) is a life-threatening disease [279] affecting about 5.7
million adults in the United States [280]. The risk of death is about 35% in the first
year after diagnosis with HF [281]. The most common risk factor of HF is
coronary artery disease (CAD) [279]. Maintenance of coronary artery function is
critical because the coronary arteries are responsible in the transport of blood
and nutrition to heart. From the 2016 American Heart Association annual report,
more than half of all cardiovascular events in both men and women is due to
CAD [282]. Moreover, the prevalence of CAD will increase about 18% by 2030
based on projections [282]. CAD due to HF has been well established. However,
the influence of HF on coronary artery stiffness is largely unknown [283].

Heart failure
HF is a syndrome which includes symptoms such as: shortness of breath
at rest and exercise, fatigue, pulmonary congestion and abnormal heart structural
and functional changes [284]. By 2030 more than 8 million adults will be
expected to have HF in the United States [280]. HF is the underlying cause of 1
in 9 deaths [285]. Patients with HF have lower stroke volume and cardiac output,
which results in overstimulation of the sympathetic nerve system and reninangiotensin aldosterone system leading to vasoconstriction, and sodium and fluid
retention. Elevation of blood pressure and increased afterload cause ventricular
wall remodeling [286]. A long-term study involving with 5143 subjects concluded
that hypertensive subjects had a greater risk of HF compared to normotensive
subjects [287]. Thus, the above evidence suggests that hypertension is the most
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common risk factor of HF. Given the lack of effective therapies [3], research
about exercise interventions to treat HF has been popular in recent years.

Coronary artery disease
Pathology of coronary artery disease (CAD) is an imbalance between
myocardial oxygen demand and supply due to the narrow or blockage in
coronary arteries [288]. One possible mechanism is lipid deposits on coronary
artery which results in artery stiffening or atherosclerosis [289]. CAD contributes
to more than half of all cardiovascular events in individuals less than 75 years old
[290]. Additionally, CAD is the underlying cause of one in seven deaths [280].
However, the effects of HF induced by increased central pressure, on coronary
artery stiffness has not been examined.

Physical activity/exercise influences on cardiovascular disease
Definition
Physical activity is defined as any bodily movement produced by skeletal
muscles that results in energy expenditure [291]. Exercise is a subset of physical
activity that is planned, structured, and repetitive and has as a final or an
intermediate objective the improvement or maintenance of physical fitness [291].

Physical activity/exercise benefits
Physical activity is a non-invasive prevention and treatment strategy for
obesity, diabetes, hyperlipidemia and CVD [292-294]. Physical activity has been
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shown to effectively control body weight, lower cholesterol, decrease blood
pressure and improve cardiovascular fitness, reduce collagen accumulation [295]
and suppress inflammatory response [296-300]. It is generally accepted that
physical activity decreases the risk of cardiovascular disease, diabetes, colon
and breast cancers [301]. Evidence suggests that physically active individuals
have lower coronary heart disease risk compared to less physically active
individuals [302-307]. Physical activity has been reported to reduce and treat
many atherosclerotic risk factors, such as high blood pressure, insulin resistance,
high triglyceride concentration and low high-density lipoprotein (HDL)
concentration [308]. Atherosclerotic lesions progression can be prevented or
slowed and O2 uptake increased during one year treadmill exercise [309]. A
meta-analysis report showed that after 12 weeks of exercise subjects had
increased HDL and decreased LDL [310]. A large population study indicated
moderate intensity exercise help reduces systolic and diastolic blood pressure
3.4 and 2.4mmHg respectively [311]. In addition, mean systolic and diastolic
blood pressure reduction in hypertensive subjects were 7.4 and 5.8mmHg
respectively and in normotensive subjects were 2.6 and 1.8mmHg respectively.
These results suggest that moderate intensity exercise decreases high blood
pressure and serves as an effective therapy for hypertensive patients. Chronic
moderate exercise has also been reported to attenuate blood glucose
concentrations in type II diabetics [312].

Influence of exercise on arterial stiffness
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It has been shown that 30 minutes of moderate cycling causes acute
reductions in arterial stiffness [313] and 60 minutes of maximal treadmill exercise
decreases lower-limb vascular stiffness [314]. Investigators proposed that
reduction in arterial stiffness was due to exercise-related incremental increases
of NO production from the vascular endothelium. Twelve weeks of exercise
training increased superoxide dismutase activity, plasma nitrite and nitrate levels
leading to decrease oxidative stress with increased vasodilation [315]. However
another experiment concluded that low intensity cycling which reduced PWV was
not associated with NO production [316]. Animal microarray results showed that
aorta prostaglandin receptor, C-type natriuretic peptide and endothelial nitric
oxide synthase genes were overexpressed with reduced aPWV after 4 weeks
treadmill running in rats [317]. These findings suggest that exercise-related
attenuations of arterial stiffness may be associated with improved endothelial
function with decreased oxidative stress.
Furthermore, 3-week moderate exercise reduced carotid and femoral
artery stiffness in type 2 diabetics with improved insulin resistance [318]. Another
study indicated nutrition and exercise interventions improved radial artery
elasticity index with decreased blood glucose, cholesterol and C-reactive protein
[319]. In summary, it is reasonable to conclude that exercise attenuates arterial
stiffness with decreased oxidative stress. However, the exercise effects on
arterial stiffness via reductions in inflammation need further investigation.

Exercise treatment in coronary artery disease
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Exercise is a treatment for patients with coronary heart disease. Low
intensity exercise improves endothelial function and is associated with increased
phosphorylation of endothelial nitric oxide (NO) synthase in coronary artery
disease patients [320]. Exercise rehabilitation after myocardial infarction helps
reduce cardiovascular mortality, sudden death and fatal or nonfatal re-infarction
[321]. Clinical meta-analysis suggests cardiovascular death was lower in
exercise rehabilitation patients [322]. A large population study shows old (~63 y)
CAD patients had lower risk of all-cause mortality after 5 years light or moderateintensity activity compared to the sedentary control group [323]. Another study
examining exercise training effects on old or young CAD patients indicates that
12 weeks moderate-intensity exercise improved both groups’ plasma lipid level,
indices of obesity and exercise capacity [324].

Exercise treatment in heart failure
Exercise is also helpful to treat patients with heart failure. Exercise used to
be restricted in HF patients due to the fear of sudden cardiac death during
exercise. Until the past few decades, numerous studies have revealed exercise
testing and training are safe for heart failure patients [325]. Exercise is beneficial
for heart failure in several ways. First, exercise helps increase peak oxygen
uptake between 12% and 31% [326]. Second, exercise improves cardiac output
[327], increases skeletal muscle mitochondrial size and density [328], and
attenuates endothelial dysfunction [329]. Third, exercise increases NO synthase
activity and expression and prevents endothelial dysfunction [329]. Recent
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research indicates that long term moderate-intensity exercise training improves
chronic HF patients’ quality of life and longevity [330]. Notably, Wisløff et al.
compared the cardiovascular effects of continuous and interval exercise training
in heart failure patients [331]. After 12 weeks of training, 3 times per week,
interval exercise trained subjects had greater aerobic capacity that was
associated with attenuation of LV remodeling compared to continuous exercise
trained subjects. Moreover, LV end-diastolic and end-systolic volumes decreased
with interval
Training, which was associated with preservation of LV ejection fraction and
reduced of pro-brain natriuretic peptide. This study suggests interval exercise
training may have greater beneficial effects compared to continuous exercise
training in patients with HF.

Mechanisms of exercise effects on arterial stiffness in physiological
settings
Low intensity chronic exercise reduces blood pressure and increases
survivability in HF rats induced by hypertension [332]. In addition, moderateintensity exercise reduces myocardial stiffness with reduced cross-linking of
collagen in older rats [333]. Other animal studies showed that exercise
interventions reduce carotid artery stiffness [334], attenuate myocardial oxygen
balance and diastolic function in swine [335] and improve survival rats with HF
[336]. The underlying mechanisms of exercise on physiological adaption has
been, in part, related to reducing oxidative stress. Moreover, an animal study
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showed that exercise increased mouse circulating endothelial progenitor cells
and reduced endothelial progenitor cell apoptosis dependent on NO synthesis
[337]. Another animal research showed 8 weeks moderate treadmill walking
increased anti-oxidant enzyme activity and prevented lipid oxidation in multiple
organs [338].
Exercise has also been shown to prevent inflammatory responses in CVDrelated conditions. Exercise had protective effects in the development of
atherosclerosis or regression of atherosclerotic lesions [339]. Another study
indicated that hypertensive women had improvements in immune function,
reduction of IL-1α, TNF-α and elevation of athero-protective cytokines IL-4 and
IL-10 after 6 months moderate exercise [19].
This emerging evidence indicates that exercise is beneficial for apparently
healthy and patient populations. However, no direct evidence demonstrates the
influence of exercise on AGE in HF conditions. An animal study conducted in an
obesity rat showed that exercise prevented AGE accumulation [340], but the
mechanisms were not examined.

High intensity exercise
In addition to the beneficial effects of exercise, there are potential risks
such as injury when performing physical activity and exercise. Risk of injury
increases with greater volume of exercise [341] and intensity [342]. High intensity
exercise dramatically increased the risk of sudden cardiac death [343, 344] and
myocardial infarction [345, 346] among individuals with cardiovascular events.
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Previous research has reported that improvements of peak oxygen uptake, left
ventricle remodeling, left ventricle function and endothelial function were greater
with high intensity exercise than moderate intensity exercise [347]. But the
underlying mechanisms remain unknown.

Summary
In summary, arterial stiffness is an independent risk factor and predictor of
cardiovascular events and all-cause mortality. Thus, investigating the
mechanisms of arterial stiffness to establish effective therapeutic interventions is
clinically significant. AGE and PVAT related oxidative stress, and inflammation
are potential risk factors for arterial stiffness. However, the influence of PVATderived AGE on arterial stiffness has not been explored. While numerous studies
focused on arterial stiffness with hypertension, few have assessed arterial
stiffness in HF model. Moreover, no evidence is available to reveal the
mechanisms of AGE accumulation with coronary artery dysfunction in nondiabetic conditions. Regular moderate-intensity physical activity has been
determined as a useful strategy to attenuate HF and coronary heart disease.
However, the mechanisms of exercise on AGE and its related signaling in nondiabetic model are poorly understood. Therefore, it is of great importance to
verify the efficacy of chronic exercise effects on coronary artery stiffness with
heart failure via PVAT-related AGE secretion.
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CHAPTER Ⅲ
Method

Aortic Banding and Exercise Training Protocols
The animals in the present study are the same animals used in recently
published work from our laboratory in the Journal of the American Heart
Association [334] and the Journal of Applied Physiology [348, 349]. Left
ventricular hypertrophy/heart failure was induced by aortic banding for a period of
24 weeks using methods previously published by our laboratory [334, 335, 350352]. Moreover, the animal model showed key characteristics of HFpEF with an
increased end-diastolic P-V slope, increased lung weight, increased LV
natriuretic peptide levels, and normal resting ejection fraction [334, 348, 349].
Male Yucatan mininature swine (29-32 kg; 8 months old) were assigned
into 4 groups (n=7 for all groups): sedentary control (CON), aortic-banded
sedentary (HF), aortic-banded chronic continuous exercise trained (HF+CONT)
and aortic-banded chronic interval exercise trained (HF+IT). Aortic bands were
placed around the ascending aorta (proximal to the brachiocephalic artery), and
a systolic transstenotic gradient of ~70 mmHg was established (74±2 , 74±2, and
72±1 mmHg for HF, HF+IT, and HF+CONT, respectively, P= not significant [NS])
under anesthesia using phenylephrine (I.V. 1-3 ug/kg/min) to maintain a distal
peripheral vascular mean aortic pressure (MAP) of approximately 90 mm Hg (90
± 1, 91 ± 2, and 89 ± 1 for HF, HF+IT and HF+CONT, respectively, P=NS) at a
heart rate of 100 beats/min (104 ± 5, 99 ± 8, and 106 ± 5 for HF, HF+IT and
HF+CONT, respectively, P=NS) as previously reported [348, 349, 353].
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Transverse aortic constriction (TAC) is the most commonly used approach to
develop pressure overload induced HF in mice [354]. However, cardiac
hypertrophy is induced within 48 hours after TAC in mice [355]. This acute
pathological alteration in the heart induced by pressure overload does not mimic
the gradual changes of myocardial remodeling. [356]. While the mini-swine
model of pressure overload-induced HF in this study better represents the human
HF condition. Moreover, HF mice induced by TAC cannot finish the 17 weeks
exercise training regimen since the 8 week survival rate is less than 50% [357].
Animals began chronic exercise training consisting of treadmill running 55
min/day, 3 days/week, for 17 weeks with gradually increases in intensity using
the following previously published protocols: continuous exercise 1) a 5 min
warm up at 1.5 mph; 2) 45 min at 2.5 mph; and 3) a 5 min cool down at 1.5 mph
[349, 353]; interval exercise 1) a 5-min warm up at 2 mph, 2) six 5-min sessions
at 3 mph with five 3-min intervals at 4 mph in between, and 3) a 5-min cool down
at 2 mph [335, 348, 358, 359]. This protocol is based off previous findings in
young, healthy miniswine that underwent a VO2max test. The VO2max of young
healthy miniswine is about 60ml/kg/min which is similar to a young, physically fit
adult male [360]. Due to the aortic banding, the intensity used in the current study
was set at ~30%-40% of VO2max for the healthy miniswine. These exercise
training protocols have been used in both healthy and HF miniswine, which has
shown to preserve left ventricular function and improve coronary micro-circulation
function [361-364]. A table with summarized animal characteristics is attached for
reference (Table 3-1). Animals were fed a standard diet averaging 15–20 g/kg

43

once daily, and water was provided ad libitum. All animal protocols were in
accordance with the “Principles for the Utilization and Care of Vertebrate Animals
Used in Testing Research and Training” and approved by the University of
Missouri Animal Care and Use Committee.
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Table 3- 1. Animal Physiological Characteristics
CON

HF

HF+CONT

HF+IT

BW, kg

46±3

48±2

48±1

49±3

SBP, mmHg

82±7

103±8*

83±7

82±6

DBP, mmHg

61±8

80±5

68±4

67±5

LV SV, ml

66±6

67±4

72±3

74±5

LV EF, %

64±3

66±3

65±3

65±4

Table 3-1. Animal Physiological Characteristics. Values are Mean±S.E.
n=7 for each group. CON, sedentary control; HF, aortic-banded heart failure
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained;
HF+IT, aortic-banded heart failure interval exercise trained. BW-body weight;
SBP-systolic blood pressure; DBP-diastolic BP; LV SV-left ventricular stroke
volume; LV EF-LV ejection fraction. *vs. all, P<0.05.
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Mechanical Stiffness Testing
Arterial stiffness was assessed as previously described [5, 8, 20, 365].
The left circumflex (LCX) and right coronary artery (RCA) were cleaned of the
surrounding adipose tissue and cut into ~1.5mm segments. The coronary arterial
ring was placed in a preheated 37C Ca2+ and Mg2+ free phosphate buffered
saline (PBS) solution in Myograph (DMT 620). The artery segment was stretched
1mm every 3 minutes until mechanical failure. The elastic modulus was
calculated from the stress-strain curve as previously described [5, 8, 20, 365]. In
brief, one-dimensional stress (t) was calculated as: t = λL/2HD, and strain (λ)
defined as: λ = Δd/d(i), where L = one-dimensional load applied, H = wall
thickness, D = length of vessel, Δd = change in diameter, and d(i) = initial
diameter. Coronary diameter and wall thickness were assessed in histological
sections, and length was measured under a dissecting microscope using
calipers. The elastic modulus was determined as the greatest r2 value from the
stress-strain curve as described previously [5]. The elastin region, coinciding with
the elastin elastic modulus (EEM), was determined as the transition point
between the toe and heel regions of the stress-strain curve, and collagen region,
coinciding with the collagen elastic modulus (CEM), was the determined greatest
r2 value prior to mechanical failure (Figure. 3-1) [5].
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Figure 3- 1. Representative of Stress-Strain curve.

Figure 3-1. Representative of Stress-Strain curve. True stress is plotted on the yaxis and true strain on the x-axis. Transition point (εT) is determined between the
toe and heel regions. The elastin elastic modulus (EEM) is the slope of the four
points prior to εT and the collagen elastic modulus (CEM) is the slope of the last
four points before the yield point.
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Coronary Perivascular Adipose Conditioned Media Experiments
The conditioned media study was performed as described previously by
our lab [5, 8, 366]. Briefly, adipose tissue surrounding the coronary artery was
removed and cultured for 24 hours in Dulbecco's modified Eagle's medium
(DMEM) containing antibiotics (20mg fat/100μl DMEM) at 37° C and 5% CO 2.
The coronary adipose conditioned media (10% of total volume) was heat
inactivated by placing in a heat block for 30 minutes at 56° C. Aortas (without the
surrounding adipose tissue) from young (4-6 month old), wild-type C57BL/6 mice
(The Jackson Laboratory) were cultured in the coronary conditioned media with
or without 1 mM AGE inhibitor (aminoguanidine, AMG) for 72 hours at 37° C and
5% CO2. The conditioned media was changed daily. After treatment, aortic
stiffness testing was performed.

Immunohistochemistry (IHC)
IHC was performed by standard procedures as previously described [5, 8].
Segments of LCX, RCA and mouse aortas were embedded with optimal cutting
temperature (O.C.T.) and frozen. Arteries were cross-sectioned (8m) , fixed on
glass slides with acetone and stained using Dako Envison+ system HRP-DAB kit
(Agilent). The following primary antibodies were used: collagen (abcam), elastin
(abcam), AGE (abcam), receptor of AGE (RAGE, abcam), nitrotyrosine (EMD),
NF-κB p65 (abcam) and scavenger receptor A (SRA, TransGenic) were applied
on slides separately and incubated at 4C overnight with pre-optimized dilutions
(Table. 3-1). The secondary HRP conjugated labeled polymer was applied for 30
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minutes at room temperature followed diaminobenzidine (DAB) application for
approximately 2 minutes until appropriate darkness achieved. Coronary PVAT
was fixed in 4% paraformaldehyde, embedded in paraffin, sectioned in 5m
thickness. Slides were deparaffinized with xylene and proteinase K was used for
antigen retrieval. Slides were stained with pre-optimized diluted primary
antibodies (Table. 3-1). Images were acquired using a Nikon 80i microscope
using a 4x, 10x and 20x objectives for the swine coronary artery, mouse aorta
and adipose tissue, respectively. Densitometry analysis was performed by
ImageJ (NIH) on the medial layer of the artery, and the data are presented as
relative density in arbitrary units (AU).
Table 3- 2. Immunohistochemistry Primary Antibody Concentration

Adipose Morphology
PVAT surrounding coronary arteries was fixed in 4% paraformaldehyde,
embedded in paraffin, and cross-sectioned (5μm). After deparaffinized, adipose
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tissue was stained with hematoxylin and eosin using standard procedures [5, 8,
367]. Digital images were acquired with a Nikon 80i microscope with 20x
objective lens in an uncompressed tiff format. Adipocyte area (μm2) and diameter
(μm) were averaged from at least 100 cells from 3 tissue sections for each
sample using ImageJ (NIH). The data for each sample was averaged, and used
to calculate the mean for each group.

Enzyme-linked Immunosorbent Assay (ELISA)
Peri-coronary adipose tissue was removed and cultured in serum-free
DMEM for 24 h at 37°C and 5% CO2 at a concentration of 20mg fat/100μl. AGE
concentration in swine coronary perivascular adipose conditioned media was
assessed by ELISA kit per the manufacturer's protocol (Cell Biolabs).

Cytokine Array
Cytokines in the peri-coronary adipose conditioned media were assessed
by Porcine Cytokine Antibody Array Kit (Abcam, ab197479). Ten cytokines
targets (IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, GM-CSF, IFNγ, TGFβ1, TNFα) were
assessed. However, only IL-6 and IL-8 were detectable. Measurement was
performed per product’s manual. Array fluorescence signals were scanned by a
laser scanner equipped with Cy3 wavelength (Typhoon 9500, GE, USA). Dots
densitometry were analyzed by ImageJ (NIH). The quantitative of cytokines were
calculated based on standard curves.
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Statistical Analysis
All data analyses were performed with Graphpad Prism 7.0. Group mean
comparisons for coronary stiffness, IHC analyses, the AGE ELISA and cytokines
array were analyzed by one-way ANOVA. Coronary PVAT culture studies were
analyzed by two-way ANOVA. Fisher’s LSD post-hoc analyses were performed
when appropriate. All data were presented as Mean±S.E. Statistical significance
was reported as P<0.05.
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Chapter Ⅳ
Result
LV Remodeling and Function
A thorough investigation of myocardial remodeling and LV function was
provided for the same animals used in the current study in recently published
work from our laboratory in the Journal of Applied Physiology [334, 348, 349]. In
brief summary, these studies demonstrated the therapeutic efficacy of chronic
exercise training on coronary vascular, isolated cardiomyocyte, and cognitive
function in a translational pressure-overload model of heart failure with potential
relevance to human HF. Aortic banding caused symptoms of heart failure in the
HF group including increased lung weight and left ventricular natriuretic peptide
levels, global concentric hypertrophic remodeling at the gross and cellular level,
and diastolic dysfunction (increased slope of the end diastolic pressure-volume
relationship). Echocardiography and pressure-volume analysis indicated ejection
fraction, fractional shortening, and stroke volume at rest were normal in HF
compared with CON animals. Chronic exercise training had a positive impact at
both the organ and molecular level in a number of different functional systems
including isolated cardiomyocyte calcium handling and contractile function, large
conductance Ca2+-activated K+ (BKCa) channel-mediated coronary vascular
function, and peripheral arterial stiffness and cognition, and we refer the reader
to these published studies for specifics [334, 348, 349].
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Exercise Prevents Coronary Artery Stiffness, ECM Remodeling, Oxidative
stress and Inflammation
Compared to CON, the combined EEM of the LCX and RCA was lower in
HF group (284±28 vs. 444±38 kPa, P<0.05; Figure 4-1A), which was associated
with reduced medial elastin protein content (P<0.05; Figure 4-1B). No differences
were observed between the CON and HF groups for either the CEM (9324±1319
vs. 10563±1272 kPa, P>0.05; Figure 4-1C) or collagen content (P>0.05; Figure
4-1D). The 16-week HF+CONT and HF+IT exercise training regimens prevented
the decrease in coronary EEM (474±38 and 511±56 kPa, respectively, P<0.05;
Figure 4-1A) and elastin content (P<0.05; Figure 1B), without influencing CEM or
collagen content (P>0.05; Figure 1C, 1D).
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Figure 4- 1. Coronary artery stiffness and arterial elastin and collagen
content
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Figure 4-1. Coronary artery stiffness and arterial elastin and collagen content.
Reduced elastin elastic modulus (EEM) (A) and elastin content (B) in HF swine
coronary was prevented by exercise training. Collagen elastic modulus (CEM)
(C) and collagen deposition (D) were not different between groups. (Data are
Mean  S.E., * vs. all, P<0.05). Representative immunohistochemistry images of
coronary artery showing medial elastin and collagen. Abbreviation: control
(CON), heart failure (HF), HF continuous exercise trained (HF+CONT), HF
interval exercise trained (HF+IT).
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Increased coronary stiffness with HF was associated with greater arterial
AGE abundance, and increased nitrotyrosine, NF-κB p65 and SRA relative to
CON (P<0.05; Figure 4-2A, 4-2C-E). Arterial RAGE was lower in HF group
compared to CON group (P<0.05; Figure 2B). Both HF+CONT and HF+IT
prevented the increase of AGE, nitrotyrosine, NF-κB p65 and SRA (P<0.05;
Figure 4-2A, 4-2C-E), and the decrease in RAGE (Figure 4-2B; P<0.05). These
findings demonstrate that a chronic continuous or interval exercise training
regimen prevents coronary artery stiffness and vascular wall ECM remodeling in
a pre-clinical mini-swine model of pressure overload-induced HF.

56

Figure 4- 2. Immunohistochemistry analysis of AGE, RAGE, oxidative
stress and inflammation level in coronary artery
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Figure 4-2. Immunohistochemistry analysis of AGE, RAGE, oxidative stress and
inflammation level in coronary artery. Greater AGE (A), nitrotyrosine (C), NF-κB
p65 (D) and scavenger receptor A (SRA) (E) in HF compared with CON, which
was attenuated by continuous and interval exercise training. (B) Receptor of
AGE (RAGE) was lower in HF compared to control, HF+CONT and HF+IT. (Data
are Mean  S.E., * vs. all, P<0.05. The nitrotyrosine abundance in HF+IT showed
decreased trending compared to HF, P+0.06). Representative
immunohistochemistry images of coronary artery showing AGE, RAGE
nitrotyrosine, NF-κB p65 and SRA alterations. Abbreviation: control (CON), heart
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failure (HF), HF continuous exercise trained (HF+CONT), HF interval exercise
trained (HF+IT).
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PVAT-related AGE Secretion, Arterial Stiffening and ECM Remodeling are
Prevented by Exercise Training
Compared with CON, HF had greater PVAT AGE abundance (P<0.05;
Figure 4-3A) and concentrations of AGE in PVAT-conditioned media (1.404±0.44
vs. 0.39±0.07μg/mL, P<0.05; Figure. 4-3B). To determine the influence of PVATderived AGE on arterial stiffness, mouse aortas were cultured with the
conditioned media and stiffness testing was performed. The EEM was reduced
after exposure to HF compared with CON PVAT-conditioned media (368±20 vs.
582±29 kPa, P<0.05; Figure 4-3C). Both HF+CONT and HF+IT exercise
attenuated or prevented the HF-related AGE accumulation in PVAT (P<0.05;
figure 4-3A), AGE secretion from PVAT (0.27±0.06 and 0.23±0.04 μg/mL,
respectively, P<0.05; Figure. 4-3B) and the PVAT-induced reduction in EEM
(542±58 and 518±22 kPa, respectively, P<0.05; Figure 4-3C). The AGE inhibitor,
AMG, prevented the PVAT-related reduction in EEM with HF (643±35 kPa,
P<0.05; Figure 4-3C). AMG also increased the EEM in HF+CONT aortic
segments (772±101 kPa, P<0.05; Figure 4-3C).
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Figure 4- 3. AGE secretion from peri-coronary adipose tissue and PVAT
derived AGE effects on aortic stiffness
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C.

Figure 4-3. AGE secretion from peri-coronary adipose tissue and PVAT derived
AGE effects on aortic stiffness. Greater peri-coronary adipose tissue AGE (A)
accumulation in HF compared with CON, HF+CONT and HF+IT. (B) AGE
concentration in HF swine coronary PVAT conditioned media was higher
compared to control and exercise training groups. (C) Exposure to HF swine
coronary conditioned media increased mouse aortic stiffness and AGE inhibitor,
AMG prevented the increased aortic stiffness. (Data are Mean  S.E., * vs. all,
P<0.05; $ vs. same group -AMG, P<0.05.) Abbreviation: control (CON), heart
failure (HF), HF continuous exercise trained (HF+CONT), HF interval exercise
trained (HF+IT), aminoguanidine(AMG).
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Effects of peri-coronary adipose conditioned media on aortic
extracellular matrix, oxidative stress and inflammatory.
To determine if coronary PVAT-derived AGE contributes to reductions in
arterial elastin and AGE accumulation, mouse aortas treated with PVAT
conditioned media were analyzed. Elastin content was decreased (P<0.05;
Figure 4-4A) and AGE was increased (P<0.05; Figure 4-4B) after culture in HFconditioned media. HF+CONT and HF+IT exercise training regimens preserved
elastin content and prevented AGE accumulation in arteries cultured in HF
PVAT-conditioned media (Figure 4-4A, 4-4B; P<0.05). AMG prevented the HFinduced reductions in arterial elastin (P<0.05; Figure 4-4A) and vascular AGE
accumulation (P<0.05; Figure 4-4B). Arterial segments treated with AMG had
lower nitrotyrosine and NF-κB p65 subunit expressions compared with segments
not treated (P<0.05, main effect of drug; Figure 4-4C, D). Collectively, these data
indicate AGE associated with PVAT promotes arterial stiffness via reductions in
elastin functionality and content, which is prevented by exercise training of two
different intensities.
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Figure 4- 4. Influence of coronary adipose conditioned media on aortic
extracellular matrix proteins
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Figure 4-4. Influence of coronary adipose conditioned media on aortic
extracellular matrix proteins, oxidative stress and inflammation. The HF coronary
adipose conditioned media decreased mouse aorta elastin content (A) and
increased AGE (B) compared to other groups while AMG prevented AGE
accumulation. (Data are MeanS.E., * vs. all, P<0.05; $ vs. same group -AMG,
P<0.05). Nitrotyrosine (C) and NF-κB p65 (D) were unchanged after cultured in
coronary adipose conditioned media, but the AGE inhibitor AMG decreased
nitrotyrosine and NF-κB p65 level. (Data are MeanS.E., * vs. all, P<0.05; $ vs.
same group -AMG, P<0.05, two-way ANOVA-Interaction effects). Representative
immunohistochemistry images of mouse aorta showing medial elastin, AGE
alterations, nitrotyrosine and NF-κB p65 level. Abbreviation: control (CON), heart
failure (HF), HF continuous exercise trained (HF+CONT), HF interval exercise
trained (HF+IT), aminoguanidine(AMG).
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Exercise Prevents Coronary PVAT Oxidative Stress, Inflammation and
Cytokines
Coronary PVAT nitrotyrosine and NF-κB p65 subunit were increased in
the HF compared with CON (P<0.05; Figure 4-5A, 5B). No differences were
observed for coronary PVAT SRA (P>0.05,Figure 4-5C) or RAGE (P>0.05,
Figure 4-5D) between the CON and HF groups. Both exercise regimens
prevented the increase in nitrotyrosine (P<0.05; Figure 4-5A). Further, HF+CONT
prevented NF-κB p65 subunit expression (P<0.05; Figure 4-5B) while reductions
with HF+IT approached significance (P=0.06; Figure 4-5B). Peri-coronary
adipose secreted more Interleukin-6 (IL-6) and IL-8 in HF conditioned media
compared to CON (265.88±30.85 vs. 146.02±30.68 pg/mL; 720.93±212.26 vs.
297.08±25.60 pg/mL, respectively, P<0.05; Figure 4-5E, F). In addition, both
continuous and interval exercise training prevented IL-6 (167.74±31.97 and
180.44±24.11 pg/mL, respectively; P<0.05; Figure 4-5E) and IL-8 (347.02±59.15
and 296.95±24.10 pg/mL, respectively; P<0.05; Figure 4-5F) secretions in
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conditioned media. Other cytokines are not detectable. PVAT cell area or
diameter were not influenced by HF or exercise training (Table 4-1).
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Figure 4- 5. Immunohistochemistry analysis of oxidative stress and
inflammation in peri-coronary adipose tissue and cytokines
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Figure 4-5. Immunohistochemistry analysis of oxidative stress and
inflammation in peri-coronary adipose tissue. Greater nitrotyrosine (A) and NF-κB
p65 (B) in HF was attenuated by exercise training. RAGE (C) and SRA (D) level
were unchanged in all groups. Excessive Interleukin-6 (IL-6) (E) and IL-8 (F)
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secretion in HF conditioned media were prevented by HF+CONT and HF+IT.
(Data are Mean±S.E., * vs. all, P<0.05; $ vs. same group -AMG, P<0.05). (Data
are MeanS.E., * vs. all, P<0.05). Representative immunohistochemistry images
of coronary artery showing peri-coronary adipose tissue nitrotyrosine, NF-κB p65,
SRA and RAGE alterations. Abbreviation: control (CON), heart failure (HF), HF
continuous exercise trained (HF+CONT), HF interval exercise trained (HF+IT).

Table 4- 1. Peri-coronary Adipose Morphology
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Chapter Ⅴ
Discussion
In this study, we examined the efficacy of, and identified a mechanism by
which, a 16-week continuous or interval exercise training regimen prevents
coronary artery stiffness in a clinically relevant, pressure overload model of HF.
The primary findings from this study include: 1) both continuous and interval
exercise training prevent coronary artery stiffness, which is associated with
preservation of arterial elastin content, and prevention of arterial AGE
accumulation; 2) PVAT-related AGE secretion promotes arterial stiffness, which
was prevented by both exercise interventions; and 3) PVAT is a source of AGE
secretion contributing to decrements in arterial elastin and AGE accumulation.
These findings provide preliminary evidence for the efficacy for two unique
exercise regimens to prevent coronary vascular stiffening with HF, and identify
PVAT-derived AGE secretion as a novel target to prevent arterial stiffening.

Exercise Training Prevents Coronary Stiffening
A thorough investigation of cardiac function and coronary micro-circulation
in the animal model used in current study was demonstrated and published in
Journal of American Heart Association and Journal of Applied Physiology by our
team [334, 348, 349]. Briefly, both continuous and interval exercise training
attenuated HF with decreased lung weight and LV brain natriuretic peptide
mRNA level. Moreover, both exercise training interventions improved coronary
blood flow and vasodilatory response [334, 348, 349].
75

A primary finding of the present study is that both chronic continuous and
interval exercise training prevents coronary artery stiffness associated with
pressure overload-induced HF. To our knowledge this is the first study
demonstrating an effect of exercise to prevent coronary artery stiffness and the
associated ECM remodeling. These findings complement recently published
work from our group in these same animals that demonstrated chronic exercise
training also preserved coronary microvascular vasodilatory function via a BK Ca
channel-mediated mechanism [348] and prevented stiffening of the carotid artery
[334], suggesting exercise can prevent pathological adaptations not only to the
peripheral vasculature but also to the coronaries all along the vascular tree (i.e.
both macro- and microvessels) in the presence of chronic pressure overload.
Aerobic exercise training has been shown to reduce both central (aortic) and
peripheral conduit artery stiffness in older and diseased adults [368-370], which
are supported by animal models providing insight to the structural changes by
which exercise attenuates arterial stiffening [16-18]. Moreover, 12 months Tai Chi
prevents AGE accumulation in healthy subjects [371] and 12 weeks moderateintensity exercise training prevents AGE accumulation in healthy women [372].
Similar to these prior studies, our findings demonstrate an effect of exercise to
preserve elastin content, and prevent AGE accumulation [17, 18, 340, 373].
Notably, we extend these findings to demonstrate similar effects for both chronic
continuous and interval exercise to prevent coronary stiffness and ECM
remodeling. Our findings are supported by previous investigations demonstrating
that continuous and interval exercise training prevent arterial stiffness in healthy
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and hypertensive subjects [12, 374]. Due to a lack of effective treatment
strategies for HF patients [3], our findings lend support for exercise training to
lower coronary artery stiffness, which in combination with previous observations
of improved coronary vascular conductance in these same animals [348] implies
an overall effect of exercise to prevent increases in vascular resistance
throughout the coronary arterial tree. Importantly, these data also show the
efficacy of chronic exercise training as a therapeutic option for treating coronary
vascular dysfunction in a setting of pressure overload-induced heart failure, using
an intensity tolerable to HF patients.

Prevention of Coronary Artery Stiffness due to Preservation of ECM
The ECM proteins elastin and collagen are primarily responsible for
contributing to mechanical stiffness of arteries [83]. Our data indicate HF
promotes coronary artery stiffness by reducing arterial elastin content, without
influencing collagen. Prior studies demonstrate other pathological conditions,
such as obesity and hyperlipidemia, as well as the elastin deficient mouse
promote arterial stiffness by reducing elastin content and/or function [8, 365,
375]. As such, the elastin elastic modulus was decreased with HF suggesting
that in addition to lower elastin content, elastin function is also diminished. This is
the first time to our knowledge it has been shown chronic continuous and interval
exercise training programs of an intensity tolerable to HF patients prevents
decrements in elastin content and function in the coronary vasculature of a preclinical model of pressure overload-induced HF. Previous investigations in rats
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have indicated the potential for this effect in the aorta following exercise training,
although these protocols used a higher training intensity and frequency
compared to the current study [17, 18].
Coronary artery stiffness mediated by AGE
In addition to changes in the ECM, we observed greater AGE
accumulation in the coronary artery of HF animals. Chronically increased plasma
glucose concentrations is a well-recognized factor contributing to AGE formation.
It is interesting to note the increase in coronary vascular AGE levels in the
current study was observed in an experimental setting absent metabolic
comorbidities. This finding recapitulates recently published observations from our
laboratory in the same swine model, which we previously attributed to increased
oxidative stress related to chronic pressure overload [5]. AGE cross-links
proteins within the arterial wall, which includes elastin and collagen, to promote
arterial stiffness [123, 376]. Further, exogenous AGE administered to rodents has
shown to promote elastin disruption and fragmentation that is associated with
arterial stiffness [129]. Thus, the increased coronary AGE may contribute to the
reductions in elastin content and impaired functionality observed with HF. Elastin
content and function were preserved with both continuous and interval exercise
programs in this study, consistent with prior work related to aortic stiffness in
aged Fisher 344 rats exercised daily at relatively low intensity [373, 377].
Collectively, these data indicate exercise training prevents coronary AGE
accumulation thereby preserving elastin content and function in a translational
swine model of heart failure.
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An important downstream effect of AGE is to signal via RAGE that, in turn,
contributes to arterial oxidative stress and inflammation. As such, we observed
an increase in nitrotyrosine abundance, and NF-κB p65 and SRA protein in the
coronary arteries of HF swine. Oxidative stress and inflammation are important
signaling mechanisms contributing to aortic stiffness both in animal models of
aging and disease [20, 365] as well as in older adults [370, 378]. More
specifically, oxidative stress activates a pro-inflammation response via the NF-κB
signaling pathway [171, 177] which in turn influences the ECM leading to arterial
stiffness [379]. Our data suggests AGE accumulation with HF increases
nitrotyrosine, NF-κB and SRA reducing elastin content and function leading to
arterial stiffness. In support of the beneficial therapeutic effects of exercise, both
chronic continuous and interval training prevented pressure overload-induced
increases in nitrotyrosine, NF-κB and SRA in the coronary arteries, suggesting
the prevention of AGE accumulation by exercise also precludes the arterial
oxidative stress and inflammatory response induced by HF.

Coronary PVAT and Arterial Stiffness
PVAT promotes age- and disease-related arterial stiffening and coronary
PVAT has been shown to predict cardiac mortality, yet the identification of factors
secreted from this fat depot still need to be elucidated [10, 380]. Consistent with
our previous findings, perivascular AGE accumulation was increased in PVAT
from HF animals [5, 20]. We also demonstrate PVAT from HF swine secretes
increased AGE that promotes impaired elastin function in vitro in isolated aortas
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from healthy mice similar to what was observed with the coronary artery. To our
knowledge, this is the first evidence to demonstrate AGE secretion from coronary
PVAT in a pre-clinical swine model of pressure overload-induced heart failure,
revealing a novel source of AGE production. Notably, the current study extends
our previous observations by demonstrating the mechanistic involvement of
PVAT-derived AGE in the reduced arterial elastin content and increased AGE
accumulation in the mouse aorta experiments, providing evidence for this fat
depot to promote ECM remodeling consistent with what was observed in the
coronary artery of HF animals. Continuous and interval exercise prevented PVAT
AGE expression and secretion, as well as the impairments to mouse aortas
exposed to PVAT-conditioned media from HF animals under our in vitro
experimental conditions including decreased elastin content, function, and
increased AGE accumulation. Use of the AGE inhibitor AMG also prevented the
detrimental impact of PVAT-conditioned media from the HF group on mouse
aortic stiffness and ECM remodeling, suggesting a mechanistic flux point by
which chronic exercise training exerts its protective effect on pressure overloadinduced coronary arterial stiffness is by reducing PVAT-related AGE secretion
and associated inflammation. These findings imply further interrogation of AGE
inhibition is warranted regarding its potential as a useful therapeutic strategy to
combat coronary arterial stiffness and dysfunction in heart failure.

Exercise Training Effects Comparable to AGE Inhibitor
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While AMG severed as prevention of AGE formation, it will probably not
be effective in patients with a long history of disease that already resulted in
extensive tissue AGE accumulation. Combined with previous findings that AMG
has been shown to prevent age-related arterial stiffness and cardiac hypertrophy
in the absence of changes in collagen and elastin content [381]. This may
suggest that the effect of AMG is related to a decrease in the AGE-induced
cross-linking of the extracellular matrix. Our PVAT study indicates that AMG
cannot preserve elastin content in CON, HF+CONT and HF+IT groups compared
to no AMG groups which is similar to previous finding. It would be logical to
predict that the chronic continuous and interval exercise training prevent the
arterial stiffness through inhibition of AGE cross-linking ECM. We may conclude
that arteria collagen is not formed cross-linking with AGE.

Effects of Oxidative Stress and Inflammation on Coronary Artery Stiffness
In the present study, we observed increased coronary PVAT nitrotyrosine
and NF-κB in the HF group which is consistent with the hypothesis that AGE
formed in adipose tissue are a result of increased oxidative stress and
inflammation [7, 127, 382, 383]. Moreover, the cytokine array results indicated
that HF promoted coronary PVAT IL-6 and IL-8 secretions. The increased IL-6
level in conditioned media was similar to our previous findings that in pathological
conditions PVAT secreted excessive IL-6 which plays a key role in regulation of
arterial stiffness [6]. Oxidative stress has been shown as a regulator of IL-8
expression [51] and oxidized lipid induces greater IL-8 accumulation [52]. Thus,
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the PVAT with nitrotyrosine abundance could be a source of IL-8 expression.
Further NF-kappa B and IL-6 family has been shown to interact with
transcriptional activation of the IL-8 gene [53]. It would be reasonable to conclude
that increased oxidative stress and NF-κB in PVAT promoted the cytokines
secretion which finally result in arterial stiffness. Exercise training prevented the
HF-related increase in PVAT nitrotyrosine abundance, NF-κB p65 subunit
expression and cytokines secretions, suggesting these processes may indeed
promote AGE production in PVAT. It is noteworthy, however, that PVATconditioned media from the HF group did not promote arterial oxidative stress
and inflammation in the mouse aorta, yet inhibition of AGE did lower normal
levels of these endpoints on a global fashion across all experimental groups
suggesting other factors such as IL-6 and IL-8 may promote vascular oxidative
stress and inflammation. However additional research is needed to verify the
effects of IL-6 and IL-8 on vascular oxidative stress and inflammation.
In addition, AGE mediated cellular signaling via oxidative stress and
inflammation is another factor to contribute arterial stiffness. In the present study
we observe that increased oxidative stress and inflammation in coronary and
PVAT which is similar to our previous data in the same animal model [5].
Considering that AGE formation in adipose tissue are a result of increased
oxidative stress and inflammation [5, 51-53]. It would be logical to predict that the
interaction between AGE and oxidative stress and inflammation are, at least,
partial key features to promote coronary artery stiffness in HF. We observed that
both chronic continuous and interval exercise prevent the oxidative stress and
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inflammation in coronary artery and PVAT which may explain that exercise
prevent AGE accumulation through inhibition of oxidative stress and
inflammation.

Limitations and Future Directions
There are several limitations of the current study. 1) As mentioned above,
arterial stiffness could be influenced by total elastin and collagen content. AGE
formed cross-linking could also contribute to stiffening arteries. It is noteworthy to
discriminate that how the elastin, collagen and cross-link affect the stiffness; 2) in
the current study we investigated AGE accumulation in coronary arteries and
PVAT as well as AGE secretion from PVAT. Further we added AGE inhibitor into
PVAT conditioned media and found that with AGE inhibition the stiffness was
prevented. With these results we conclude that PVAT secreted AGE is a key
factor in arterial stiffness. However, it is unknown if we will observe the similar
results when culturing the healthy artery and fat depot directly with AGE. It is
noteworthy to run these experiments to elucidate whether HF has the similar
effects as AGE influences on coronary artery stiffness. In addition, we discussed
the association between oxidative stress and AGE formation. But we still need
further investigation to determine the PVAT secreted AGE is formed from
oxidized lipids; 3) this study has 4 groups: CON, HF, HF+CONT and HF+IT. Due
to the funding and experiment limitations, CON+CONT and CON+IT are not
included. Though we do not observe any differences between HF+CONT and

83

HF+IT, whether there is any differences or changes between CON, CON+CONT
and CON+IT is unclear;
and 4) women have lower risk rate of cardiovascular diseases at all ages
compared to men, however the low estrogen level due to post-menopausal will
dramatically increase the risk of CV events [384, 385]. It is noteworthy to
consider the sex difference influences on coronary artery stiffness with heart
failure. Thus, the future study design is focused on aortic-banding and
ovariectomy effects on female mini-swine to mimic the HF- and aging-related
women. Previous findings indicated that 8 weeks exercise preserved endothelial
function and nitric oxide to reduce arterial calcification in ovariectomized rats
[386]. This provides support that exercise potentially is a therapeutic strategy for
after menopause women in cardiovascular diseases.

Perspectives
The prevalence of HF is expected to increase 46% by 2030 and given the
lack of effective therapies, our findings suggest that chronic continuous and
interval exercise training could be a therapeutic strategy for reducing arterial
stiffness in HF patients [3, 387]. Recently we reported chronic exercise training
preserved coronary microvascular vasodilatory function [348] and prevented
carotid artery stiffness [334] in this swine model of pressure overload-induced
heart failure. Our current data extend these findings demonstrating the efficacy of
chronic continuous and interval exercise to prevent conduit coronary artery
stiffness. The therapeutic benefits of both modes of chronic exercise were
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through the preservation of elastin function in the coronary artery, which was due
to reduced PVAT-derived AGE. Thus, our study provides support for chronic
continuous and interval exercise training as a therapeutic option for HF patients
at an intensity that is tolerable for this population.
In summary, we provide novel evidence for chronic continuous and
interval exercise to preserve normal coronary arterial stiffness associated with
ECM remodeling in a pre-clinical mini-swine model of pressure overload-induced
HF. We elucidate that PVAT derived AGE plays a key role in coronary artery
stiffness associated with vascular wall remodeling, oxidative stress and
inflammation, which is prevented by chronic continuous and interval exercise.
Previous findings (Table 5-1) are summarized to demonstrate that continuous
and interval exercise training improves cardiac and coronary artery function and
prevents carotid artery stiffness [334, 348, 349].The primary findings (Table 5-2)
and proposed mechanisms (Figure 5-1) are summarized demonstrating the
effects of chronic low intensity continuous and interval exercise training to
prevent coronary artery stiffness with HF via inhibition of PVAT derived AGE.
Collectively, our data lend support that the therapeutic potential of exercise
intervention to prevent coronary artery stiffness with tolerable intensity to HF
patients, and suggest the beneficial effects via PVAT AGE inhibition.
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Table 5- 1. Continuous and interval exercise training improves cardiac and
coronary artery functions and prevents carotid artery stiffness in HF
miniswine induced by aortic-banding
CON

HF

HF+CONT

HF+IT

LV BNP mRNA

Normal

Increased

Attenuated

Attenuated

LV fibrosis area and density

Normal

Increased

Attenuated

Attenuated

LV collagen area

Normal

Increased

Attenuated

Attenuated

Carotid Artery PEM

Normal

Increased

Attenuated

Attenuated

Carotid Stiffness Index

Normal

Increased

Attenuated

Attenuated

CBF

Normal

Decreased

Preserved

Preserved

CVC

Normal

Decreased

Preserved

Preserved

Table 5-1. CON, sedentary control; HF, aortic-banded heart failure
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained;
HF+IT, aortic-banded heart failure interval exercise trained; LV BNP-left
ventricular brain natriuretic peptide; PEM-Peterson elastic modulus; CBFcoronary blood flow; CVC-coronary vascular conductance.
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Table 5- 2. Continuous and interval exercise training prevents coronary
artery stiffness with the reduction of PVAT derived AGE
Coronary EEM, kPa
Coronary CEM
Coronary Elastin‡
Coronary Collagen‡
Coronary AGE‡
Coronary
Nitrotyrosine‡
Coronary NFkB‡
Coronary PVAT AGE‡
PVAT secreted AGE,
μg/mL

CON
HF
HF+CONT
HF+IT
284±28
444±38*
474±38
511±56
9324±1319 10563±1272 10958±1582 10684±1623
1
0.67
1.057
0.97
1
0.9
1.008
0.95
1
1.66
1.173
1.17
1

1.31

1.03

1.09

1
1

1.33
1.70

0.98
1.29

1.03
1.32

0.39±0.07

1.404±0.44*

0.27±0.06

0.23±0.04

Table 5-2. CON, sedentary control; HF, aortic-banded heart failure
sedentary; HF+CONT, aortic-banded heart failure continuous exercise trained;
HF+IT, aortic-banded heart failure interval exercise trained; EEM-elastin elastic
modulus; CEM-collagen elastic modulus; PVAT-perivascular adipose tissue;
AGE-advanced glycation end products. ‡-fold change relative to CON. *vs. all,
P<0.05.
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Figure 5- 1. Proposed mechanisms by which HF and exercise training
influence coronary artery stiffness

Figure 5-1. CONT-continuous exercise training; IT-interval exercise
training; PVAT-perivascular adipose tissue; AGE-advanced glycation end
products.
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